Compare BioNano Genomics Inc (BNGO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Verisign, Inc. — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Verisign, Inc. trades at $269.58 (market cap $24.47B). The key difference: Verisign, Inc. is far larger — about 1853.8× BioNano Genomics Inc's market cap, and Verisign, Inc. pays a 1.21% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | VRSN | |
|---|---|---|
Market Cap | $13.20M | $24.47B |
Sector | Health | Technology |
52-Week High | $4.92 | $310.00 |
52-Week Low | $1.09 | $211.49 |
Enterprise Value | $15.81M | $25.70B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
VeriSign (VRSN) trades at $270.31, up 0.07% with a bullish technical outlook. The stock shows strong fundamentals with 2025 revenue of $1.66B, net income of $825.7M, and exceptional 49.96% net margin. Recent Q1 2026 earnings beat expectations at $2.34 EPS. Analyst consensus is bullish with 57% buy ratings and $327.67 price target, representing 21% upside potential. The company maintains its monopoly position in .com/.net domain registry with predictable revenue growth.
VRSN presents a compelling investment case with stable cash flows and dominant market position, though trading at premium valuations (P/E 29.87). Key risks include contract renewals, AI disruption potential, and high debt levels. The upcoming Q2 2026 earnings report on July 23 will be critical for validating growth trajectory. Current levels offer attractive entry for long-term investors seeking defensive tech exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
